Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Plus Therapeutics (PSTV – Research Report), with a price target of $4.00.
Jason McCarthy has given his Buy rating due to a combination of factors that highlight Plus Therapeutics’ promising outlook. The company has made significant progress in its clinical trials, particularly with the completion of the Phase 1 ReSPECT-LM trial and the ongoing Phase 2b ReSPECT-GBM study. These advancements indicate potential efficacy and safety of their treatments, which are crucial for future success.
Additionally, Plus Therapeutics has strengthened its financial position with recent equity financing and grants, providing a runway into the fourth quarter of 2025. The anticipated commercial launch of the CNSide diagnostic platform later this year further supports the company’s growth prospects. These elements combined suggest a positive trajectory for Plus Therapeutics, justifying the Buy rating.
According to TipRanks, McCarthy is an analyst with an average return of -22.3% and a 23.99% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Actinium Pharmaceuticals, and Medicus Pharma Ltd.
In another report released on March 28, H.C. Wainwright also maintained a Buy rating on the stock with a $5.50 price target.